Our Firm is actively evaluating legal claims on behalf of individuals who suffered severe liver damage resulting in hospitalization, transplantation or death, allegedly due to their use of a Tylenol-brand medicine.
New York, New York (PRWEB) June 12, 2014
Tylenol lawsuits (http://www.tylenollawsuitcenter.com/) filed on behalf of individuals who allegedly suffered severe liver damage due to the acetaminophen in over-the-counter Tylenol products continue to move forward in the U.S. District Court, Eastern District of Pennsylvania, Bernstein Liebhard LLP reports. According to court documents, the litigation’s next Status Conference has been scheduled for Tuesday, June 17, 2014 at 10:00 a.m. The Court has directed Liaison Counsel to submit an agenda at least two business days prior to the conference. (In Re: Tylenol (Acetaminophen) Marketing, Sales Practices and Products Liability Litigation, MDL No. 2436)
“Our Firm is actively evaluating legal claims on behalf of individuals who suffered severe liver damage resulting in hospitalization, transplantation or death, allegedly due to their use of a Tylenol-brand medicine. We are pleased to see the federal litigation moving forward,” says Bernstein Liebhard LLP, a nationwide law firm representing the victims of defective drugs and medical devices. The Firm is offering free legal reviews to consumers who were allegedly harmed by a Tylenol-brand over-the-counter medication.
Tylenol Liver Damage Allegations
Acetaminophen is the active ingredient in dozens of over-the-counter medications, including Tylenol brand products marketed by Johnson & Johnson and McNeil Consumer Healthcare. According to a recent report published by The Philadelphia Inquirer, 78,000 people require emergency room care every year due to toxic reactions to acetaminophen. Such injuries also result in about 33,000 hospitalizations every year.*
In 2011, the U.S. Food & Drug Administration (FDA) announced that it would limit the amount of acetaminophen in prescription medications to 325 mg per tablet. According to a notice posted on the Federal Register, the new limits went into affect on January 14, 2014. In April, the FDA announced that prescription drugs containing more than 325 milligrams of acetaminophen were no longer considered safe and were being voluntarily removed from the market. The agency also reminded pharmacists to stop dispensing high-dose prescription acetaminophen products.**
The FDA has not imposed similar limits on the amount of acetaminophen in over-the-counter acetaminophen products. In August 2013, Bloomberg.com reported that over-the-counter Extra Strength Tylenol caplets each contain 500 mg of acetaminophen, well over the new limits for prescription medications set by the FDA. That same month, McNeil Consumer Healthcare announced that it would add new, more prominent warnings regarding the risk of liver damage to the labels of Tylenol-brand medication.***
According to court documents, more than 140 Tylenol lawsuits have been filed in the federal litigation underway in the Eastern District of Pennsylvania. All of the claims accuse Johnson & Johnson and McNeil of failing to provide adequate warnings regarding the association between the acetaminophen in Tylenol and liver damage. In many cases, Tylenol lawsuit plaintiffs claim that liver damage occurred even though the drugs were used in accordance with label directions, and resulted in hospitalization, the need for liver transplantation or death.
Alleged victims of Tylenol and liver damage may be entitled to compensation for injury-related damages. To learn more about filing a Tylenol lawsuit, please visit Bernstein Liebhard LLP’s website. To arrange for a free legal review, please call 800-511-5092.
*articles.philly.com/2014-02-17/news/47382323_1_acetaminophen-poisoning-tylenol-maker-kate-trunk, Philadelphia Inquirer, February 17, 2014
**latimes.com/science/sciencenow/la-sci-sn-extra-strength-acetaminophen-fda-20140428,0,6108401.story, LA Times, April 28, 2014
***bloomberg.com/news/2013-08-29/j-j-adds-warning-to-tylenol-caps-on-acetaminophen-risk.html, Bloomberg.com, August 29, 2013
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3 billion on behalf of our clients. The Firm has been named by The National Law Journal to the Plaintiffs Hot List, recognizing the top plaintiffs firms in the country, for the past 12 consecutive years. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list every year since it was first published in 2003.
Bernstein Liebhard LLP represents the victims of defective drugs and medical devices on a contingency-fee basis, and our clients are never expected to pay attorneys fees unless their case results in a successful recovery on their behalf. New York States contingency fee cap rules generally limit those fees to 33 1/3% of the total recovery. As a result, the Firms fees can be significantly lower than those assessed by attorneys in other states, which depending on the law may amount to as much as 40% or more of a plaintiff’s recovery.
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
ATTORNEY ADVERTISING. © 2014 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Felecia L. Stern, Esq.
Bernstein Liebhard LLP